Discover

BNGO
Bionano Genomics, Inc.
1.17
2 x 0.84
2 x 1.44
bid
ask
+
0.04
3.54%
2 @ 08:28 AM
1.17 +0.00 (0.00%)
Ytd-23.53%
1y-64.55%
1.12
day range
1.18
1.06
52 week range
5.50
Open1.16Prev Close1.13Low1.12High1.18Mkt Cap13.43M
Vol232.78KAvg Vol150.75KEPS-4.46P/EN/AForward P/E-0.41
Beta2.38Short Ratio3.81Inst. Own12.81%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1350-d Avg1.20200-d Avg1.431yr Est1.00
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-142024-090-0.32N/AN/A
2024-08-072024-060-0.24N/AN/A
2024-08-072024-060N/AN/AN/A
2024-05-082024-030-0.6N/AN/A
2024-05-082024-030N/AN/AN/A
2024-03-052023-120-0.96N/AN/A
Upgrade / Downgrade
DateFirmActionFromTo
2024-11-15Ladenburg ThalmannDowngradeBuyNeutral
2024-05-16BTIGUpgradeBuyBuy
2024-03-07ScotiabankUpgradeSector OutperformSector Outperform
2023-11-13Maxim GroupDowngradeBuyHold
2023-08-10BTIGUpgradeBuyBuy
Profile
Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Insider Holder
DateNameRelationQuantityDescription
2024-06-02CHAUBEY ALKA PH.D.Officer48.25KStock Award(Grant)
2024-06-02DIXON JONATHAN VGeneral Counsel18.02KStock Award(Grant)
2024-06-02HOLMLIN R ERIKChief Executive Officer122.32KStock Award(Grant)
2024-06-02KAMA GULSENChief Financial Officer16.00KStock Award(Grant)
2023-06-12MAMUSZKA HANNAHDirector65.79KPurchase
2024-06-02OLDAKOWSKI MARKChief Operating Officer64.70KStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Vanguard Group Inc2.19M443.76K2.15%
2024-09-29Geode Capital Management, LLC882.85K178.69K0.87%
2024-09-29Blackrock Inc.614.16K124.31K0.60%
2024-09-29GMT Capital Corp530.26K107.32K0.52%
2024-09-29Citadel Advisors Llc249.07K50.41K0.24%
2024-09-29Northern Trust Corporation147.13K29.78K0.14%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Vanguard Total Stock Market Index Fund1.36M276.16K1.34%
2024-09-29Vanguard Extended Market Index Fund505.29K102.27K0.50%
2024-10-30Fidelity Extended Market Index Fund492.06K99.59K0.48%
2024-08-30Vanguard Health Care Index Fund208.60K42.22K0.20%
2024-10-30Fidelity Total Market Index Fund166.23K33.65K0.16%
2024-10-30Fidelity Series Total Market Index Fund116.33K23.55K0.11%
Split
SplitDate
1 : 602025-01-27
1 : 102023-08-07